NVO Share Price

Open 45.46 Change Price %
High 45.82 1 Day -0.73 -1.58
Low 45.31 1 Week -0.47 -1.03
Close 45.34 1 Month 2.15 4.98
Volume 2352582 1 Year -1.70 -3.61
52 Week High 47.98
52 Week Low 30.89
NVO Important Levels
Resistance 2 45.81
Resistance 1 45.62
Pivot 45.49
Support 1 45.06
Support 2 44.87
NYSE USA Most Active Stocks
RAI 65.40 -2.23%
RAI 65.40 -2.23%
EMC 29.05 0.97%
EMC 29.05 0.97%
EMC 29.05 0.97%
SE 40.68 -0.78%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
PCS 11.84 -0.92%
BAC 23.64 -2.27%
More..
NYSE USA Top Gainers Stocks
POM 26.93 26.79%
POM 26.93 26.79%
GLF 0.34 25.93%
GLF 0.34 25.93%
SSI 1.90 25.83%
SSI 1.90 25.83%
SDLP 3.15 17.98%
FNP 35.24 12.02%
FNP 35.24 12.02%
DMD 6.35 9.48%
More..
NYSE USA Top Losers Stocks
ENL 15.81 -66.25%
ENL 15.81 -66.25%
ENL 15.81 -66.25%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
MHR 0.15 -42.31%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
STP 0.53 -39.77%
More..

Novo Nordisk A/S (NYSE: NVO)

NVO Technical Analysis 4
As on 17th Aug 2017 NVO Share Price closed @ 45.34 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 38.37 & Buy for SHORT-TERM with Stoploss of 43.14 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVO Target for August
1st Target up-side 43.86
2nd Target up-side 44.88
3rd Target up-side 45.91
1st Target down-side 40.94
2nd Target down-side 39.92
3rd Target down-side 38.89
NVO Other Details
Segment EQ
Market Capital 84204396544.00
Sector Healthcare
Industry Drug Manufacturers - Other
Offical website http://www.novonordisk.com
NVO Address
NVO
Novo All
Bagsvaerd, 2880
Denmark
Phone: 45 44 44 88 88
Fax: 45 44 49 05 55
NVO Latest News
Interactive Technical Analysis Chart Novo Nordisk A/S ( NVO NYSE USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novo Nordisk A/S
NVO Business Profile
Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes Care segment covers insulins, GLP-1 analog, obesity, and oral antidiabetic drugs, as well as other protein related products comprising glucagon, protein related delivery systems, and needles. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation. The company sells its products primarily in North America, China, Japan, Algeria, Argentina, Australia, Brazil, India, Turkey, and European countries through its subsidiaries, distributors, and independent agents. Novo Nordisk A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.